Sign In
Buy CRBP
$7.38
-0.160 (-2.12%)
At Close: Jun 03, 2026
Corbus Pharmaceuticals Reports Second Quarter Financial Results and Corporate Updates
11:05am, Thursday, 06'th Aug 2020
* RESOLVE-1 Phase 3 study of lenabasum for treatment of systemic sclerosis on schedule for topline data this summer * Phase 2b study of lenabasum for cystic fibrosis topline results on schedule in Q3
Corbus Pharmaceuticals Completes Enrollment in DETERMINE Phase 3 Study of Lenabasum for Treatment of Dermatomyositis
01:25pm, Wednesday, 05'th Aug 2020
* 12-month, double-blind, placebo-controlled, multi-national study enrolled 176 participants * Topline results expected in fourth quarter of 2021 * Dermatomyositis is a rare, systemic autoimmune
Corbus Pharmaceuticals to Present at Two Upcoming Investor Conferences
12:05pm, Monday, 03'rd Aug 2020
Norwood, MA, Aug. 03, 2020 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transforma
Corbus Pharmaceuticals to Report Second Quarter Results on August 6, 2020
12:05pm, Thursday, 30'th Jul 2020
* Management to host conference call and webcast on Thursday, August 6 at 8:30 a.m. ETNorwood, MA, July 30, 2020 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus”
Corbus Pharmaceuticals Strengthens Balance Sheet with up to $121 Million in New Capital
12:05pm, Wednesday, 29'th Jul 2020
* Aggregate of $71 million of ATM proceeds executed at weighted average price of $7.70 per share * Received $20 million first tranche from $50 million debt facility with K2 HealthVentures * Cash on
After 6 Years Corbus Shareholders Face The Ultimate Milestone: The Imminent Release Of Lenabasum's Phase 3 Data
11:29pm, Tuesday, 21'st Jul 2020
With 4 potential indications, Lenabasum is Corbus' potential Blockbuster therapy ($1 billion+/Revenue/Year).
Are Options Traders Betting on a Big Move in Corbus Pharmaceuticals (CRBP) Stock?
02:02pm, Tuesday, 21'st Jul 2020
Investors need to pay close attention to Corbus Pharmaceuticals (CRBP) stock based on the movements in the options market lately.
Corbus Pharmaceuticals (CRBP) Receives a Buy from RBC Capital - Markets
06:55am, Monday, 20'th Jul 2020
In a report issued on July 16, Brian Abrahams from RBC Capital reiterated a Buy rating on Corbus Pharmaceuticals (CRBP
BidaskClub Lowers Corbus Pharmaceuticals (NASDAQ:CRBP) to Sell
05:48am, Sunday, 19'th Jul 2020
BidaskClub downgraded shares of Corbus Pharmaceuticals (NASDAQ:CRBP) from a hold rating to a sell rating in a research report report published on Wednesday morning, BidAskClub reports. CRBP has been t
Better Buy: GW Pharmaceuticals vs. Corbus Pharmaceuticals
08:21pm, Friday, 17'th Jul 2020
Medical marijuana is known to have helped with many health issues and has even worked better than conventional medicines in some cases. Both Cambridge, U.K.-based GW Pharmaceuticals (NASDAQ: GWPH) a
Royal Bank of Canada Has $947,000 Position in Corbus Pharmaceuticals Holdings Inc (NASDAQ:CRBP)
08:36pm, Thursday, 16'th Jul 2020
Royal Bank of Canada lifted its holdings in shares of Corbus Pharmaceuticals Holdings Inc (NASDAQ:CRBP) by 15.9% during the first quarter, according to the company in its most recent Form 13F filing w
What Does Corbus Pharmaceuticals Holdings' (NASDAQ:CRBP) CEO Pay Reveal?
06:38pm, Wednesday, 15'th Jul 2020
This article will reflect on the compensation paid to Yuval Cohen who has served as CEO of Corbus Pharmaceuticals...
Zacks: Analysts Anticipate Corbus Pharmaceuticals Holdings Inc (NASDAQ:CRBP) to Post -$0.38 Earnings Per Share
05:44am, Tuesday, 14'th Jul 2020
Analysts expect that Corbus Pharmaceuticals Holdings Inc (NASDAQ:CRBP) will post earnings per share of ($0.38) for the current fiscal quarter, Zacks reports. Four analysts have provided estimates for
$3.90 Million in Sales Expected for Corbus Pharmaceuticals Holdings Inc (NASDAQ:CRBP) This Quarter
02:12am, Monday, 13'th Jul 2020
Analysts predict that Corbus Pharmaceuticals Holdings Inc (NASDAQ:CRBP) will report sales of $3.90 million for the current fiscal quarter, according to Zacks. Four analysts have provided estimates for
Corbus Pharmaceuticals Appoints George Golumbeski, Ph.D., to Board of Directors
12:05pm, Wednesday, 08'th Jul 2020
Dr. Golumbeski formerly led corporate and business development at Celgene and NovartisAppointment adds unique skill set to Corbus Board ahead of several key data readouts this.
